Want to see BDMD full AI Analyst Report?
BDMD Stock Chart & Stats
$1.76
$0.13(1.73%)
At close: 4:00 PM EST
$1.76
$0.13(1.73%)
Day’s Range― - ―
52-Week Range$0.76 - $4.29
Previous Close$7.55
Volume323.07K
Average Volume (3M)238.60K
Market Cap
$47.13M
Enterprise Value$66.66M
Total Cash (Recent Filing)$178.32K
Total Debt (Recent Filing)$19.30M
Price to Earnings (P/E)―
Beta-0.82
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding40,979,380
10 Day Avg. Volume117,298
30 Day Avg. Volume238,602
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.21
Price to Sales (P/S)1.68
P/FCF Ratio-27.26
Enterprise Value/Market Cap1.41
Enterprise Value/Revenue2.96
Enterprise Value/Gross Profit3.53
Enterprise Value/Ebitda-2.75
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained high gross margins indicate the product set carries strong unit economics and potential pricing power. That margin profile can support recovery in operating profitability once revenue stabilizes or cost bases are adjusted, enabling reinvestment in R&D and commercialization over the medium term.
Manageable Leverage And Equity CushionDebt at roughly 0.62x equity suggests the balance sheet retains room to raise or restructure capital if needed. A meaningful equity cushion today provides flexibility to pursue commercialization or strategic initiatives without immediately triggering solvency stress, supporting medium-term options.
Early International Clinical/commercial TractionFirst procedures abroad demonstrate emerging real-world adoption and international market entry. Early clinical/commercial validation in new geographies expands addressable market and supports a multi-market commercialization strategy that can deliver durable revenue streams as rollout scales.
Bears Say
Sharp Revenue Decline And Loss In 2025A ~29% revenue drop and swing to a deep operating loss materially weakens the company's scale economics and raises structural questions about demand or product competitiveness. Sustained revenue erosion magnifies fixed-cost leverage and makes durable margin recovery more difficult without clear demand restoration.
Persistent Negative Operating And Free Cash FlowChronic negative operating and free cash flow indicate the business cannot self-fund growth or cover capital needs, increasing reliance on external financing. Over months to a few years this raises dilution, refinancing risk, and constrains investments in commercialization or product development.
Weakening Equity And Negative Return On EquityDeclining equity and a sharply negative ROE reduce financial flexibility and can erode investor confidence. If losses persist, the equity cushion will shrink further, limiting options for financing and increasing the cost of capital needed to support recovery or international expansion.
Baird Medical Investment Holdings News
BDMD FAQ
What was Baird Medical Investment Holdings’s price range in the past 12 months?
Baird Medical Investment Holdings lowest stock price was $0.76 and its highest was $4.29 in the past 12 months.
What is Baird Medical Investment Holdings’s market cap?
Baird Medical Investment Holdings’s market cap is $47.13M.
When is Baird Medical Investment Holdings’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Baird Medical Investment Holdings’s earnings last quarter?
Currently, no data Available
Is Baird Medical Investment Holdings overvalued?
According to Wall Street analysts Baird Medical Investment Holdings’s price is currently Overvalued.
Does Baird Medical Investment Holdings pay dividends?
Baird Medical Investment Holdings does not currently pay dividends.
What is Baird Medical Investment Holdings’s EPS estimate?
Baird Medical Investment Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Baird Medical Investment Holdings have?
Baird Medical Investment Holdings has 40,979,380 shares outstanding.
What happened to Baird Medical Investment Holdings’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Baird Medical Investment Holdings?
Currently, no hedge funds are holding shares in BDMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Baird Medical Investment Holdings Stock Smart Score
Company Description
Baird Medical Investment Holdings
Based in China, Baird Medical Investment Holdings Limited and its associated entities specialize in engineering and commercializing microwave ablation medical apparatus. These sophisticated instruments are employed in the minimally invasive management of a diverse array of benign and malignant tumors, notably targeting thyroid nodules, hepatic carcinomas, pulmonary cancers, and mammary lesions. The organization was established in 2012, with its corporate headquarters situated in Guangzhou, China.
Technical Analysis
Ownership Overview
―
Insiders
0.06% Mutual Funds
0.61% Other Institutional Investors
99.33% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---